secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kairos Pharma, LTD. (KAPA)
CIK:        0001962011
Form:       8-K
Filed at:   2026-06-04T12:00:39+00:00
Accession:  0001493152-26-027200
Event type: m_and_a
Sentiment:  positive
Materiality: 0.55
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kairos Pharma signs term sheet to acquire CL-741, a Phase 1-ready c-MET inhibitor; outlines 2026 milestones
--------------------------------------------------------------------------------

- Acquiring worldwide rights to CL-741, an oral type IIb c-MET kinase inhibitor targeting EGFR-mutated lung cancer and esophageal/gastric cancers.
- CL-741 is Phase 1-ready; Phase 1 study initiation planned for H2 2026.
- ENV-105 Phase 2 trial in prostate cancer continues; more trial sites expected by year-end.
- ENV-105 Phase 1 in NSCLC results anticipated by Q3 2026.
- Over $8M in non-dilutive funding; low monthly burn rate highlighted.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1962011/000149315226027200/0001493152-26-027200-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1962011/000149315226027200/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-027200

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer